Mr. Hugh MacNaught reports

VENTRIPOINT DIAGNOSTICS LAUNCHES TARGETED CONGENITAL HEART DEFECT MARKETING PROGRAM, SETTING STAGE FOR MULTI-SEGMENT GROWTH

Ventripoint Diagnostics Ltd. has launched a targeted marketing program focused on the diagnosis and monitoring of congenital heart defects (CHD). The initiative is designed to solidify Ventripoint's leadership position in this high-need clinical area, while laying the foundation for expansion into other rapidly growing segments including cardio-oncology, pulmonary hypertension, heart failure and valvular heart disease.

The new program will spotlight the company's flagship VMS+ system, which delivers MRI-comparable volumetric and functional cardiac measurements using standard echocardiography. This capability eliminates many of the patient and workflow barriers associated with cardiac MRI -- particularly critical for CHD patients, who often require frequent monitoring from infancy through adulthood.

"CHD patients face a lifetime of imaging, yet many cannot access MRI due to cost, availability or clinical limitations," said Hugh MacNaught, president and chief executive officer of Ventripoint Diagnostics. "Our VMS+ technology solves that challenge by enabling fast, accurate and comfortable assessments using widely available ultrasound equipment. By leading in CHD, we are also building the clinical credibility and installed base needed to accelerate adoption in other high-value segments."

The CHD-focused marketing program will include:

• Collaboration with industry partners -- continuing to actively work with partners such as ASCEND Cardiovascular to cross-market and promote AI enhanced echocardiography solutions;
• Specialized clinical education -- building on the company's relationships with pediatric and adult congenital cardiology centres to demonstrate workflow integration and patient benefits;
• Patient advocacy engagement -- continuing the collaboration with the Ollie Hinkel Heart Foundation and developing relationships with other CHD advocacy organizations to increase awareness of advanced, accessible imaging options;
• Key opinion leader (KOL) partnerships -- working with the company's clinical advisers to publish CHD case studies and peer-reviewed data that reinforce VMS+ as the standard of care for functional cardiac assessment without MRI.

By establishing a leadership position in CHD, Ventripoint expects to accelerate uptake in additional clinical areas where fast, non-invasive and accurate cardiac volumetric analysis is in demand -- such as monitoring heart damage in cancer patients (cardio-oncology), tracking right heart changes in pulmonary hypertension, assessing cardiac performance in heart failure and assessing suitability of patients for valve repair and replacement procedures in addition to monitoring outcomes.

"Each of these markets represents a significant growth opportunity, but CHD offers a unique platform for proving our value proposition in the most challenging and underserved patient population," added Mr. MacNaught. "From there, our addressable market expands exponentially."

Ventripoint will provide updates on program milestones and commercial progress in its upcoming quarterly communications.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (artificial intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary knowledge-based reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide the company's future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the United States, Europe and Canada.

We seek Safe Harbor.